More on RGNX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $7.24 |
|
|||
| Open | $7.53 | ||||
| 52 Wk High | $25.00 | ||||
| 52 Wk Low | $7.07 | ||||
| Day High | $7.68 | ||||
| Day Low | $7.17 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 1,276,586 | ||||
- Stifel Reiterates Buy Rating on Regenxbio Inc. (RGNX)
- Regenxbio stock gains on positive gene therapy trial data
- REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting
- Regenxbio settles patent dispute with Sarepta for $39M
- Form 8-K REGENXBIO Inc. For: Sep 23
- Form 4 REGENXBIO Inc. For: Aug 25 Filed by: Ciongoli Gregory Austin
- Form 3 REGENXBIO Inc. For: Aug 25 Filed by: Ciongoli Gregory Austin
- Regenxbio Inc. (RGNX) PT Lowered to $21 at H.C. Wainwright
- Form 8-K REGENXBIO Inc. For: Aug 25
- RegenxBio adds new board member as two directors retire
Entities mentioned with RGNX
- FDA | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Definitive Agreement | View Related Stories »
- Morgan Stanley | View Related Stories »
- 13G | View Related Stories »
- Show More...
